ArticleDiscover oncology2025
CTHRC1/TGF-β/Smad axis serves as therapeutic targets in inhibiting oral squamous cell carcinoma by mediating ferroptosis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in ferroptosis mechanisms and therapeutic potential in head and neck squamous cell carcinoma.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCollagen triple helix repeat containing 1 (CTHRC1) is an oncogene in numerous human cancers including oral squamous cell carcinoma (OSCC). However, whether and how CTHRC1 influences OSCC progression through ferroptosis has not been completely clarified.
methodsqRT-PCR were conducted to assess CTHRC1 expression in OSCC. The proliferation of OSCC cells were assessed through 5-ethynyl-2'-deoxyuridine (EdU) assay, colony formation, and CCK-8 assays. Flow cytometry was used to analyze the apoptotic cells of OSCC cells. Ferroptosis was assessed based on the amounts of MDA, lipid ROS, intracellular Fe
resultsPronounced overexpression of CTHRC1 was observed in OSCC cell lines (SCC-9, CAL-27 and SCC-25). Knockdown CTHRC1 overtly inhibited cell proliferation but induced apoptosis in OSCC cells. Moreover, silencing of CTHRC1 could stimulate ferroptosis, as well as inhibit the activation of TGF-β/Smad pathway. Treatment with SRI-011381, a TGF-β/Smad pathway specific agonist, significantly reversed the promoting effect of CTHRC1 silencing on ferroptosis in OSCC cells.
conclusionsOur findings indicate that knockdown of CTHRC1 stimulates ferroptosis in OSCC through inhibiting TGF-β/Smad pathway, which provides important experimental data and theoretical basis for the management, diagnosis, and treatment of OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.